<img height="1" width="1" src="https://www.facebook.com/tr?id=914352225269004&amp;ev=PageView%20&amp;noscript=1">

The Heart Study

We are looking for volunteers to take part in a new research study investigating a potential new treatment that may reduce the risk of cerebro-cardiovascular disease in people with additional risk factors(elevated lipoprotein(a)).


Elevated lipoprotein(a) is a risk factor for cerebro-cardiovascular disease. Cerebro-cardiovascular disease is a term for conditions that affect blood flow to your brain, such as carotid artery disease and stroke. Genetic factors play a major role in lipoprotein(a) concentrations. This study aims to evaluate the safety and tolerability of a potential new treatment for elevated lipoprotein(a).

Eligibility
● 18 to 65 years of age
● BMI 18 to 35 kg/m2
● No uncontrolled or serious diseases
Location
  • SA
Duration
  • Up to 56 weeks

Read more
Heart Icon-1

If you take part in the research study, there will be:

Remuneration

Eligible participants will be reimbursed for their time

Convenience

Short overnight stay

Contribution to medical research

Help investigate a potential new treatment that could improve the lives of individuals with cerebro-cardiovascular disease risk factors

Register your interest now

or scroll down to read more about this study

About this study

01

Who can take part in this study?

-

To take part in this study, you will need to meet all the following (other criteria
apply):


● 18 to 65 years of age
● BMI 18 to 35 kg/m2
● Weight greater than 50kg

02

Who is unable to take part in this study?

+

Unfortunately, if any of the following apply to you, this study is not the right fit for
you:

  • Any uncontrolled or serious disease

 A history of any of the following:

  • Acute coronary syndromes
  • Myocardial infarction
  • Stable angina
  • coronary or other revascularization
  • ischemic stroke or transient ischemic attack
  • atherosclerotic peripheral arterial disease.

Please note, additional eligibility criteria apply.

03

How long will this study take?

+

If you are deemed eligible for the study, your participation is expected to last up to
56 weeks.

You will be required to attend the clinic for a 2-night inpatient stay and at
least 15 clinical visits.

Participation in this research is voluntary, and you may withdraw from the study at
any time.

04

What is the purpose of this study?

+

This study aims to evaluate the safety and tolerability of a potential new treatment
when administered as a single dose to individuals with elevated Lipoprotein(a).

This study aims to provide valuable insights into the potential treatments suitability
for future clinical trials and its potential as a treatment option for individuals with
elevated lipoprotein(a), to reduce the risk of cerebro-cardiovascular disease.

05

What is Lipoprotein(a) and cerebro-cardiovascular disease?

+

Lipoprotein(a) is a type of cholesterol-carrying particle in the blood. Lipoprotein (a) contains a specific protein called apolipoprotein (a), which is linked to LDL cholesterol.

High levels of lipoprotein(a) are associated with an increased risk of cerebro-cardiovascular disease which is a term used to describe conditions that affect blood flow to your brain, such as carotid artery disease and stroke.
heart attacks and strokes.

Genetic factors play a significant role in determining lipoprotein(a) levels.

06

Why is this study important?

+

Lipoprotein(a) is a risk factor for cerebro-cardiovascular disease disease, and current therapies targeting traditional risk factors like LDL cholesterol may not effectively reduce the cerebro-cardiovascular disease risk associated with high lipoprotein(a) levels.

Screening for elevated lipoprotein(a) is recommended for individuals at moderate to high risk of cerebro-cardiovascular disease.

New therapies are being developed to lower lipoprotein(a) levels and reduce cerebro-cardiovascular disease risk. Lowering lipoprotein(a) levels may help prevent cerebro-cardiovascular disease without causing harmful side effects.

07

Who is sponsoring this study?

+

This study is being sponsored by Argo Biopharma. Argo Biopharma is a clinical
stage biotech company that has committed to developing a new generation of
siRNA drugs to provide better treatments for global patients.

08

Where is my nearest study site?

+

This study is being conducted at:

  • CMAX - 21-24 North Terrace, Adelaide SA 5000

09

What if I have other questions about the study?

+

We're here for you! Please send an email to our friendly Patient Experience team:

patientexperience@evrima.com.au

Help make medical research breakthroughs happen.